Brief: Sequana Medical H1 Net Loss Deepens To EUR 11.9 Mln

Sequana Medical NV

02/09/2021 06:08

Sept 2 (Reuters) - SEQUANA MEDICAL NV  SEQUA.BR :
    * ANNOUNCES H1 2021 RESULTS AND PROVIDES BUSINESS UPDATE
    * TOTAL LIQUIDITY POSITION OF EUR 21.8 MILLION PROVIDES CASH
RUNWAY INTO Q2 2022
    * ALFAPUMP® - POSITIVE RESULTS FROM SECOND INTERIM ANALYSIS
OF
POSEIDON PIVOTAL STUDY; AWAITING FDA APPROVAL ON POSEIDON
PIVOTAL STUDY EXPANSION
    * ALFAPUMP® - FDA REGULATORY SUBMISSION NOW EXPECTED IN
MID-2023
DUE TO WORLDWIDE SUPPLY SHORTAGE OF ELECTRONIC COMPONENTS;
EUROPEAN COMMERCIAL ACTIVITIES AND CLINICAL STUDIES UNAFFECTED
    * ASSUMING NO FURTHER COVID-19 RELATED RESTRICTIONS, COMPANY
EXPECTS TO GENERATE 2021 REVENUES, ON A PRO RATA BASIS, IN LINE
WITH PERIODS BEFORE REDUCED MANUFACTURING SUPPLY
    * H1 NET LOSS EUR 11.9 MILLION VERSUS LOSS OF EUR 9.6
MILLION YEAR
AGO
    * H1 EBIT LOSS OF EUR 11.5 MILLION VERSUS LOSS OF EUR 8.9
MILLION
YEAR AGO
    * H1 REVENUE EUR 23,000 VERSUS EUR 0.6 MILLION YEAR AGO
    * CONTINUES TO MONITOR IMPACT OF COVID-19 ON ITS ACTIVITIES,
PARTICULARLY IN RESPECT TO POSEIDON AND ITS EUROPEAN COMMERCIAL
BUSINESS

Source text for Eikon:  ID:nGNX8lDWSM 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))